Fatty Liver May Start in the Gut, Not the Liver, New Study Finds
Most of what I read about fatty liver treats it as a liver problem, full stop. Cut the alcohol, cut the sugar, maybe add milk thistle, and hope the liver heals itself. A new study out of Michigan Medicine makes the case that for at least one severe form of fatty liver disease, the actual problem might be starting somewhere else entirely, in the gut.
- Michigan Medicine researchers found an experimental tripeptide drug candidate, called DT 109, reversed severe fatty liver disease (MASH) in mice and monkeys.
- It did not work by acting on the liver directly. It worked by shutting down a gut bacterium, Clostridium perfringens, that produces ammonia and damages the intestinal lining.
- Once that lining is damaged, toxins leak from the gut into the liver through the portal vein, a known driver of liver inflammation and scarring.
- DT 109 is an unapproved drug candidate tested only in animals so far. No probiotic, supplement, or liver support product on the market is validated by this study.
The study ran in mice and then in nonhuman primates. There is no human data at all.
Understanding Animal ResearchCC BY 2.0
Illustrative. A generic animal facility, not the one where this work was done.
The route the study proposes, from the gut to the liver.
Direction only. The study reports the sequence, not the size of any step in it.
A liver disease that starts in the intestines
Researchers tested an experimental tripeptide drug candidate called DT 109 in mice and nonhuman primates with metabolic dysfunction associated steatohepatitis, or MASH, a severe and progressive form of fatty liver disease. Instead of targeting the liver, DT 109 went after a specific gut bacterium, Clostridium perfringens, that overgrows in MASH and produces excess ammonia. That ammonia damages the intestinal lining, and once that barrier is compromised, bacterial toxins travel straight to the liver through the portal vein, driving the inflammation and fibrosis that define the disease.
A liver lobule. Everything the gut sends arrives here first, which is the argument this study makes.
NIH NIAIDWikimedia CommonsCC BY 4.0
An NIH BioArt teaching diagram, not an image from this study.
What the study actually found
In both mice and nonhuman primates, DT 109 suppressed Clostridium perfringens growth, cut ammonia production, strengthened the gut barrier, and reduced liver inflammation and MASH severity. The primate data matters more than usual here, since primate gut microbiota and liver physiology track much closer to human biology than mouse models do. The same compound has separately shown effects on limiting arterial plaque and calcification in primates too, which points to one mechanism with reach beyond just the liver. The study was published in the Journal of Clinical Investigation on July 1, 2026, with Michigan Medicine and ScienceDaily both covering the same findings.
- DT 109
- Unapproved drug candidate
- 2
- Species tested: mice and primates
- 1
- Bacterium targeted
- 0
- Human trials
Honest caveat
DT 109 is a drug candidate, not a supplement, and it is not available to anyone right now. Every result here comes from mice and nonhuman primates. There is no human trial data yet, and this is the first study to show this exact mechanism, so it has not been independently replicated. Nothing here validates any existing probiotic, gut health supplement, or liver support product. The mechanism is specific to this one compound targeting this one bacterium, not a general case for taking a probiotic to protect your liver.
What this means for you
a reason to be skeptical of any liver detox product that only claims to work on the liver itself
You cannot buy DT 109 and there is nothing actionable to do with it yet. What is genuinely useful here is the reframe. If gut barrier damage can drive a serious liver disease in animal models, it is a real reason to treat gut health and liver health as connected rather than separate concerns, and a reason to be skeptical of any liver detox product that only claims to work on the liver itself. I will be watching for human trial data on this mechanism, and for any independent lab that replicates the Clostridium perfringens connection.
Primary sources
- Metabolic dysfunction associated steatohepatitis exacerbated by Clostridium perfringens derived ammonia is attenuated by tripeptide DT 109, Journal of Clinical Investigation, published July 1, 2026, DOI 10.1172/JCI200522.
- Michigan Medicine, "Drug candidate treats severe fatty liver disease by protecting the gut in animal models," July 7, 2026.
- ScienceDaily summary, July 11, 2026.
Common questions
What is DT 109 and can I take it?
DT 109 is an experimental tripeptide drug candidate tested so far only in mice and nonhuman primates. It is not an approved medication and it is not sold as a supplement, so there is no human safety or dosing data yet, and nothing about buying or taking it right now.
Does this mean probiotics or gut health supplements can fix fatty liver?
No. This study tested one experimental drug candidate against one specific gut bacterium, Clostridium perfringens, and its ammonia output. It does not test or validate any existing probiotic, prebiotic, or liver support supplement on the market. The honest takeaway is a mechanism worth watching, not a product recommendation.
Why would gut bacteria affect the liver at all?
The gut and liver share a direct blood supply through the portal vein. When the intestinal lining is damaged, bacterial byproducts like ammonia and toxins can travel straight to the liver and drive inflammation there. Researchers call this the gut liver axis, and it is why gut barrier health and liver health are increasingly treated as one connected system rather than two separate problems.
Stay Curious.
Better health isn't found in a single article. It's built through curiosity, evidence, and small discoveries over time. Join thousands exploring longevity, gut health, recovery, nutrition, and the tools that truly make a difference.